BiotechTube
Isarna Therapeutics

Isarna Therapeutics

Munich, Germany· Est.
isarna-therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $78M

Overview

Isarna Therapeutics is a private, clinical-stage biotech leveraging deep expertise in antisense oligonucleotide design to target TGF-β, a key mediator of fibrosis and disease progression. The company has built a portfolio targeting specific TGF-β isoforms, with its lead program in Phase 2a for retinal diseases and preclinical assets for NASH and cancer. Backed by a syndicate of German venture capital and public investors, Isarna aims to pioneer a new class of therapeutics in a complex but high-potential biological pathway.

OphthalmologyFibrotic DiseasesOncology

Technology Platform

Antisense oligonucleotide (ASO) platform for precise modulation of specific TGF-β isoforms at the mRNA level.

Funding History

3
Total raised:$78M
Series C$20M
Series B$33M
Series A$25M

Opportunities

The unmet need in treating the fibrotic component of retinal diseases like nAMD and DME represents a significant commercial opportunity alongside standard anti-VEGF care.
Furthermore, successfully modulating TGF-β in larger indications like NASH and oncology could unlock blockbuster potential given the lack of effective therapies and the pathway's central role in disease progression.

Risk Factors

The primary risks include clinical failure of the lead candidate ISTH0036, the inherent biological complexity and potential safety challenges of targeting the multifunctional TGF-β pathway, and intense competition from other modalities and companies in fibrosis and immuno-oncology.
As a private firm, there is also ongoing financial risk related to securing future funding rounds.

Competitive Landscape

Isarna competes in the TGF-β inhibition space with companies using various approaches, including monoclonal antibodies (e.g., Sanofi's fresolimumab), small molecules, and other oligonucleotide platforms. In ophthalmology, it faces competition from established anti-VEGF giants and other fibrosis-targeting candidates. In NASH and oncology, the competitive field is crowded with numerous large pharma and biotech players, making differentiation through isoform-specific targeting critical.

More companies in RNA Therapeutics (non-mRNA) →More companies in Germany →